SLC5A2 and diabetes mellitus: These data from the CVOTs have led to updated guidelines that prioritize the use of medications from the SGLT-2 inhibitor and GLP-1ra classes in diabetes patients, to decrease the risks of atherosclerotic CVD, hospitalization for heart failure, and progression of kidney disease [139].